Vir Biotechnology
General Information | |
Business: | We are a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Infectious diseases are one of the leading causes of death worldwide and cause hundreds of billions of dollars of economic burden each year. We believe that now is the time to apply the recent and remarkable advances in immunology to combat infectious diseases. Our approach begins with identifying the limitations of the immune system in combating a particular pathogen, the vulnerabilities of that pathogen and the reasons why previous approaches have failed. We then bring to bear powerful technologies that we believe, individually or in combination, will lead to effective therapies. |
Industry: | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) |
Employees: | 206 |
Founded: | 2016 |
Contact Information | |
Address | 499 Illinois Street, Suite 500, San Francisco, CA 94158, US |
Phone Number | (415) 906-4324 |
Web Address | http://www.vir.bio |
View Prospectus: | Vir Biotechnology |
Financial Information | |
Market Cap | $2187.9mil |
Revenues | $11.7 mil (last 12 months) |
Net Income | $-122.4 mil (last 12 months) |
IPO Profile | |
Symbol | VIR |
Exchange | NASDAQ |
Shares (millions): | 7.1 |
Price range | $20.00 - $20.00 |
Est. $ Volume | $142.9 mil |
Manager / Joint Managers | Goldman Sachs/ J.P. Morgan/ Cowen and Company/ Barclays |
CO-Managers | - |
Expected To Trade: | 10/11/2019 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |